(HWM) – Analyzing Howmet Aerospace’s Short Interest
read more ​Â
Media
Bitcoin Zigzags Around $70,000: What Is Going On?
- by
- November 1, 2024
Bitcoin’s (CRYPTO: BTC) continued its volatile trading action around the $70,000 mark on Friday morning as traders and analysts try to pin down key support and resistance levels. read more ​Â
Media
Magna International Misses On Q3 Earnings, Plans To Resume Buybacks From Q4
- by
- November 1, 2024
Magna International’s Q3 earnings miss prompts plans to resume share buybacks in Q4, while shares rise in premarket trading. read more ​Â
Media
Top 3 Energy Stocks That Are Preparing To Pump In November
- by
- November 1, 2024
Latest Ratings for BORR Date Firm Action From To Jun 2020 Citigroup Maintains Neutral Apr 2020 BTIG Downgrades Buy Neutral Mar 2020 Citigroup Maintains Neutral View More Analyst Ratings for BORR View the Latest Analyst Ratings read more ​Â
Media
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
- by
- November 1, 2024
Novo Nordisk’s ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. read more ​Â
Media
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- by
- November 1, 2024
read more ​Â
Media
JPMorgan To Pay Investors $151 Million After SEC Flags ‘Various Law Violations’
- by
- November 1, 2024
The SEC charged JPMorgan in five separate enforcement actions for failures including misleading disclosures to investors. read more ​Â
Media
LyondellBasell Q3 Results Miss Estimates, Signals Softer Demand And Rising Costs For Q4
- by
- November 1, 2024
LYB shares down after reporting Q3 results below expectations. Higher feedstock costs and seasonality may impact Q4. read more ​Â
Media
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
- by
- November 1, 2024
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities. read more ​Â